World
China biotech flow picks up as Everest seals US$250 million deal
April 9, 2026
South China Morning Post
Scroll
China’s biopharmaceutical sector is seeing an uptick in deal-making, with sovereign wealth funds from Singapore and the United Arab Emirates joining Chinese state-backed investors to back next-generation drug developers. Shanghai-based Everest Medicines agreed to spend US250 million to acquire a Singapore company holding rights to 14 chronic-disease treatments across the Asia-Pacific region, according to a stock exchange filing on Wednesday.
Its Singapore unit will acquire 100 per cent of...
South China Morning Post
Coverage and analysis from Hong Kong. All insights are generated by our AI narrative analysis engine.
Hong Kong
Bias: lean left